主要不眠症に対する偽薬のプラセボ効果:ランダム化対照試験のメタ分析
Bo Jiang1, Yi-Nan Wang1, Jun Zhang2
1School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Journal of sleep research
|February 15, 2026
まとめ
偽りの治療は,一次性不眠症に対する有意なプラセボ効果を示し,睡眠品質のスコアを改善しています. しかし,ポリソムノグラフィのような客観的な睡眠測定では,大きな変化は見られず,その影響が主に心理的であることを示した.
科学分野:
- 統合的・補完的医療とは
- スリープ・メディシン (睡眠医学)
- 臨床研究方法論 臨床研究方法論
背景:
- 主要不眠症は,一般的な睡眠障害である.
- 治療は一般的な治療法ですが,プラセボと比較して特定の効果については議論されています.
- 偽りの治療のコントロールは,真の治療効果を隔離するために非常に重要です.
研究 の 目的:
- 主要性不眠症に対する偽の治療に関するランダム化対照試験 (RCT) を体系的にレビューし,メタ分析する.
- 偽ののプラセボ効果の大きさを定量化するために.
- 偽の治療の研究におけるプラセボ効果に影響を与える要因を特定する.
主な方法:
- PRISMAのガイドラインに従って,体系的な文献レビューとメタ分析を行いました.
- 主要不眠症の患者で偽の治療の有効性を比較するRCTを複数のデータベースで検索しました.
- 4348件の試験をスクリーニングした後に36件のRCTが含まれ,Cochraneツールを使用してバイアスのリスクが評価されました.
主要な成果:
- 偽りの治療は,ピッツバーグの睡眠品質指数 (PSQI) のスコアを大幅に低下させた (WMD = 1.38, 95% CI = 0.90-1.86).
- 偽りの治療はまた,不眠症の重症度指数 (ISI) のスコアを大幅に低下させました (WMD = 2.58,95%CI = 1.46-3.69).
- ポリソムノグラフィやアクティグラフィの測定では,大きな変化は見られなかった.
結論:
- 偽りの治療は,主性不眠症の臨床試験で顕著なプラセボ効果を示しています.
- 観察されたプラセボ効果は,主観的な睡眠品質測定に主に影響を及ぼします.
- 偽薬の治療におけるプラセボ効果の大きさは,使用された特定の偽薬技術によって異なります.
関連する概念動画
01:54The Placebo Effect
6.9K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.9K
02:07Blind Procedures
13.7K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.7K
01:19Management of Insomnia
685
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
685
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
628
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
628
01:11Blinding
4.0K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.0K